Sai Parenterals Ltd

Sai Parenteral's Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sai Parenterals Ltd

₹ 545 -0.68%
05 Jun - close price
Company website BSE: 544742 NSE: SAIPARENT
About

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]

Key Points

Business Profile[1][2]
Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.

Website BSE NSE
  • Market Cap ₹ 2,409 Cr.
  • Current Price ₹ 545
  • High / Low ₹ 570 / 400
  • Stock P/E 169
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 5.97 %
  • ROE 4.88 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Debtor days have improved from 253 to 173 days.

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of 8.64% over last 3 years.
  • Company has high debtors of 173 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE IPO Nifty IPO

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2025 Mar 2026
96 198
100 172
Operating Profit -4 26
OPM % -4% 13%
3 3
Interest 5 8
Depreciation 6 8
Profit before tax -12 12
Tax % -43% -6%
-7 13
EPS in Rs -1.80 2.98
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
97 154 163 381
78 122 124 342
Operating Profit 19 32 39 39
OPM % 19% 21% 24% 10%
0 1 1 9
Interest 6 11 12 18
Depreciation 6 9 8 17
Profit before tax 7 13 20 12
Tax % 40% 33% 28% -20%
4 8 14 14
EPS in Rs 6.13 6.36 5.43 3.23
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 58%
TTM: 134%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 48%
TTM: -1%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 9%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 7 13 13 22
Reserves 24 61 80 469
69 119 94 333
34 75 85 600
Total Liabilities 134 268 272 1,424
44 70 53 364
CWIP 2 0 0 212
Investments 0 0 0 0
88 198 219 848
Total Assets 134 268 272 1,424

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
-13 -30 33 93
-19 -46 0 -274
24 79 -36 596
Net Cash Flow -8 2 -2 415
Free Cash Flow -30 -72 41 -184
CFO/OP -54% -94% 86% 253%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 231 302 283 173
Inventory Days 83 143 199 259
Days Payable 140 203 225 224
Cash Conversion Cycle 174 242 256 208
Working Capital Days 19 72 79 -161
ROCE % 16% 17% 6%

Shareholding Pattern

Numbers in percentages

3 Recently
Mar 2026Apr 2026
51.16% 51.16%
5.73% 5.73%
12.86% 12.86%
30.25% 30.25%
No. of Shareholders 7,6877,687

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

Concalls